Bristol Myers, in its second major takeover of the year, will buy the schizophrenia and Alzheimers drugmaker Karuna Therapeutics for…
Das Übernahmekarussell im Biotech-Sektor dreht sich weiter. Am letzten Handelstag vor Weihnachten wird die Übernahme von Karuna Therapeutics durch Bristol-Myers…
Das Übernahmekarussell im Biotech-Sektor dreht sich weiter. Am letzten Handelstag vor Weihnachten wird die Übernahme von Karuna Therapeutics durch Bristol-Myers…
NEW YORK (dpa-AFX) - Der US-Pharmakonzern Bristol-Myers Squibb will seinen Konkurrenten Karuna Therapeutics übernehmen. Die…
Bristol Myers Squib agreed to buy Karuna Therapeutics for $14 billion on Friday, gaining a promising experimental schizophrenia drug.…
Bristol-Myers Squibb to acquire Karuna for $14 billion - WSJ…
Microsoft, Booking Holdings, Bristol-Myers Squibb, Equifax hand First Solar are included in this Analyst Blog.…
…
These two pharma stocks have sizable dividend yields. Which is the better buy right now?…
These two pharma stocks have sizable dividend yields. Which is the better buy right now?…
The answer might depend on the kind of investor you are.…
The Global Gene Therapy Market Size was valued at USD 7.65 Billion in 2022 and the Worldwide Gene Therapy Market…
Shares of Bristol Myers Squibb Co. slipped 0.75% to $51.47 Thursday, on what proved to be an all-around great trading…
…
By John Vandermosten, CFA
NASDAQ:ALLR
Early Results - Phase II Stenoparib
Allarity Therapeutics, Inc. (NASDAQ:ALLR) provided an update to investors on its…
Bristol Myers Squibb Co. BMY announced an additional $3 billion share buyback program on Thursday, boosting the full authorization to…
Bristol Myers Squibb Co. BMY said late Wednesday that its board has declared a quarterly dividend of 60 cents a…
Major multiple myeloma market players include Amgen Inc., Johnson & Johnson, Takeda Pharmaceuticals Company Limited, Novartis AG, Sanofi, Teva Pharmaceuticals…
The Global Melanoma Therapeutics Market Size was valued at USD 5.03 Billion in 2022 and the Worldwide Melanoma Therapeutics Market…
…
…
Taking a closer look at one of the largest companies in the pharmaceutical industry…
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global…
Companies covered in this report are AbbVie Inc., Sanofi, Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La…
Avidity Biosciences soared 35% in pre-market trading after announcing a global licensing and research collaboration with Bristol-Myers Squibb Co...…
…
Avidity Biosciences Inc. RNA said Tuesday it’s expanding its cardiovascular collaboration with Bristol Myers Squibb Co. BMY in a deal…
The Global Non-Hodgkin Lymphoma Therapeutics Market Size was valued at USD 7.85 Billion in 2022. The Worldwide Non-Hodgkin Lymphoma Therapeutics…
…
…
Companies covered in this study are Novartis, AstraZeneca, Merck & Co., Inc, Bristol-Myers Squibb, Pfizer, Eli Lilly and Company, Gilead…
…
Bristol Myers Squibb (BMY) and 2seventy bio, Inc.s efforts to seek approval for the label expansion of Abecma for earlier…
Bei den Einzelwerten geben die Aktien von Bristol Myers Squibb zum Handelsstart um rund vier Prozent nach. Dabei spielt auch…
Bristol Myers Squibb slumps as FDA convenes advisory panel for drug application…
Bristol-Myers Squibb Co (NYSE:BMY) shares fell almost 5% after the company announced that a Food and Drug Administration (FDA) decision…
London (www.aktiencheck.de) - Bristol-Myers Squibb-Aktienanalyse von Barclays:
Die Analysten von Barclays stufen die Aktie von Bristol-Myers Squibb Company (ISIN: US1101221083, WKN:…
These are the stocks posting the largest moves in the premarket.…
Shares of Bristol Myers Squibb, 2seventy bio fell early Monday as FDA said it would miss a regulatory action date…
…
The week is off to an ugly start for some pharmaceutical investors.
Bayer said it is halting a trial for asundexian,…
…
Bristol Myers Squibb shares dip as market shows mixed results…
…
Bristol-Myers Squibb slashed, Energizer hit with 3 downgrades: 4 big analyst cuts…
The hypertrophic cardiomyopathy market dynamics are anticipated to change during the forecast period (2023–2032) due to the expected launch of…
The stock isnt nearly as risky as its low valuation suggests.…
…
Theres a lot more at stake than bragging rights.…
…